Diseases & Conditions
Grants & Contracts
News & Events
See the list of featured NIAID clinical trials below or view the complete list of NIAID studies recruiting participants on ClinicalTrials.gov.
This 10- to 20-minute survey is available for patients with eczema or parents of patients with eczema. These questions will help us learn more about patient experiences to improve current research and guide future research.
NIAID is committed to advancing the understanding of how and why autoimmune diseases such as rheumatoid arthritis occur.
The purpose of this study is to see if treatment with a medication called Nucala® (mepolizumab), given along with standard asthma care, makes children less likely to have asthma attacks.
Airway irritation, cough and bronchial spasm are common symptoms in patients with airway inflammatory diseases such as asthma. The primary focus of this exploratory study is to determine if there is an increase in tissue temperature in airway mucosa during asthma exacerbation.
Scientific evidence has shown that, over the past two decades, the combination of cockroach allergy and cockroach exposure is one of the most important factors contributing to the dramatic increase in asthma morbidity seen in inner city children with asthma.
Determining how memory T helper type 2 (Th2) initiate recall responses to aeroallergens has the potential to change the therapeutic approach to allergic asthma, the most common asthma subtype.
This trial is a randomized, double-blind, placebo controlled trial designed to test whether two years treatment of preschool children aged 2-3 years of age at high risk for asthma with omalizumab (anti-IgE) for two years will prevent the progression to childhood asthma, as reflected by a reduction in the prevalence of active asthma in the Final 12 months during 2 year observation period off study drug.
There is a need for people to take part in research studies to learn more about diseases and how to treat them.
This will be a single site, mechanistic study of asthmatic subjects and healthy, non-asthmatic controls involving a baseline characterization visit and a research bronchoscopy visit.
This protocol describes a single site mechanistic study to investigate microRNAs (miRNAs) that are differentially expressed in the airway epithelium of patients with asthma at baseline and in response to allergen challenge.
This study tests the hypothesis that an increase in pathogenic bacteria within the infant airway leads to increased airway inflammation, decreased airway function and ultimately airway obstruction throughout the first one to two years of life.
The primary objective of this NIAID study is to further characterize the natural history of idiopathic CD4 lymphocytopenia (ICL).
This study serves as a centralized sequencing protocol for NIH human subjects research studies to facilitate standardization and consolidate accrual of genotype and phenotype data for participating programs.
This study will evaluate patients with abnormal immune function that results in recurrent or unusual infections or chronic inflammation.
To learn more about when and why IBD may develop in some people with primary immune dysregulation.
This study will determine the long term medical condition and daily functioning of participants with CGD after a transplant and if possible, compare these results to participants who do not undergo a transplant.
To see if RFA is a safe and effective treatment for CGD-related liver abscesses.
This study is a prospective non-controlled, non-randomized Phase I/II clinical trial to assess the safety, feasibility and efficacy of cellular gene therapy in patients with chronic granulomatous disease.
This protocol is designed to study the techniques needed to develop gene therapy or other treatments for certain inherited immune system diseases.
To collect data on people with primary immune deficiency disorders.
Currently, people with immune disorders fall outside of guidance for COVID-19 vaccination, as they are typically excluded from vaccine trials.
The goal of this study is to evaluate the safety and efficacy of BIO 300 Oral Suspension to improve lung function in patients that were previously hospitalized with COVID-19 related pulmonary complications.
The main purpose of NIAID's TICO is to learn if new treatments are safe and can help people in the hospital with COVID-19 get better and go home faster.
The primary purpose of NIAID's ACTIV-5/BET study is to evaluate the efficacy of investigational therapeutics in adults hospitalized for COVID-19.
This is a national study that will compare the immune response to additional COVID‐19 vaccine doses in participants with autoimmune disease who did not mount an adequate response to the initial vaccination regimen.